74 / 490
72
SCIENTIFIC PROGRAMME
| PROGRAMME AND EXHIBITION GUIDE
SATURDAY 30 APRIL 2016
INTERDISCIPLINARY RADIOBIOLOGY
CLINICAL BRACHYTHERAPY PHYSICS
RTT
YOUNG
> CyberKnife for prostate cancer patients – early results of 350
patients irradiation
L. Miszczyk, A. Namysl-Kaletka (Poland), A. Napieralska, G. Wozniak,
M. Stapor-Fudzinska, G. Glowacki, K. Grabinska
PV-0089
> Stereotactic body radiotherapy for localized prostate cancer: a 7-year
experience
Y.W. Lin (Taiwan), K.L. Lin, L.C. Lin
PV-0090
> Early salvage RT for PSA recurrence postprostatectomy improves
biochemical progression free survival
A.B. Hopper (USA), A.P.S. Sandhu, J.P. Einck
PV-0091
PRESIDENTIAL SYMPOSIUM
12:00 - 12:35 | AUDITORIUM
12:05 > Patient centric approach: myth or fact?
Speaker: P. Poortmans (The Netherlands)
SP-0092
AWARD LECTURE: EMMANUEL VAN DER SCHUEREN AWARD
12:35 - 13:15 | AUDITORIUM
12:35 > Introduction
Chair: V. Valentini (Italy)
12:40 > Did I do it right? What was the result? Process and outcomes in
radiotherapy
Speaker: A. Barrett (UK)
SP-0093
Symposium with proffered papers
HOT TOPICS IN SABR: TIME FOR RANDOMISED CLINICAL TRIALS?
14:30 - 15:45 | ROOM 2
The session will be dedicated to the role of randomised clinical trials in SABR. After reviewing the
existing evidenced and lessons learned by David Palma, some biological endpoints will be presented
by Martin Brown. Because the results obtained with stereotactic radiosurgery (SRS) and stereotactic
ablative radiotherapy (SABR) have been impressive they have raised the question of whether classic
radiobiological modeling is appropriate for large doses per fraction. Finally, Marianne Aznar will talk
about developments in image guidance, treatment delivery methods (i.e. VMAT, etc...), dose calcula-
tion algorithms and their common impact on the development of future clinical trials as well as the
issue of common standards in normalisation and reporting of the prescription dose.
Chair: E. Lartigau (France)
Co-chair: R. Ruggieri (Italy)